The U.S. Supreme Court has ruled against Matrixx Initiatives, allowing a class-action lawsuit by investors to go forward after the company failed to disclose initial reports of consumers who experienced adverse side effects. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments